Gastrointestinal Cancer

Overview

colorectal cancer survivor Duke Cancer Institute's Gastrointestinal Cancer program applies the findings of our labs to our clinical practices — continually improving the outcomes of our patients.

Patients with GI cancers benefit from our refined approaches to risk assessment, advances to improve responses to existing treatments, and development of more effective treatments.

Colorectal cancer, pancreatic cancer, and hepatocellular carcinoma (liver cancer), are especially challenging to treat and the death rates for these cancers are high, especially when the cancer is diagnosed late and has metastasized (spread) from one part of the body to another.

However, more effective medical treatments for gastrointestinal cancers and widespread screening to detect cancer early, particularly in the case of colorectal cancer, has improved survival rates.

Strong translational research, led by Duke investigators, has significant potential to continue to improve diagnosis, prevention and treatment across a range of gastrointestinal cancers.

We are especially committed to nurturing this basic science and clinical research in the areas of diagnosis, prevention, and quality of life by engaging young faculty members through mentoring and funding opportunities.

Treatment & Research

pancreatic cancer survivorBuilding on Duke’s biomarker (substances found in the blood or tissues) and immunotherapy discoveries, the Gastrointestinal Cancer program is advancing translational research to bring about new treatments, improve the effectiveness of current treatments, and prevent or lessen treatment side effects. 

We strive to match screening, disease monitoring, and/or treatment choices to the individual genetic or biological markers of our patients. 


 

Make an Appointment

To make an appointment, please call 888.275.3853. For more information on gastrointestinal cancer care at Duke Health, visit:

To find a doctor, visit Find A Specialist.

Clinical Trials

We have many gastrointestinal cancer trials open, including for colorectal cancer and cancers of the stomach, esophagus and other digestive organs.

SEARCH OUR CLINICAL TRIALS

Additional Contacts

Wanda Honeycutt, Assistant Research Practice Manager
Phone: 919.681.9455